申请人:FLYNN Daniel L.
公开号:US20110118271A1
公开(公告)日:2011-05-19
The present invention relates to novel kinase inhibitors and modulator compounds useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferrably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
本发明涉及新型激酶抑制剂和调节剂化合物,可用于治疗各种疾病。更具体地,本发明涉及这样的化合物、激酶/化合物加合物、治疗疾病的方法以及化合物的合成方法。优选地,这些化合物对于调节Raf激酶及其疾病多态性的激酶活性是有用的。本发明的化合物在哺乳动物癌症治疗中,特别是人类癌症治疗中,包括但不限于恶性黑色素瘤、结直肠癌、卵巢癌、乳头状甲状腺癌、非小细胞肺癌和间皮瘤方面具有应用价值。本发明的化合物也在类风湿性关节炎和视网膜病变治疗中,包括糖尿病性视网膜神经病变和黄斑变性方面具有应用价值。